Prostate Cancer Foundation VL

Results from TRITON2: Treatment of mCRPC with Rucaparib - Alan Bryce

Details
(Length of Discussion: 8 min) Charles Ryan and Alan Bryce discuss TRITON2 results that provide a compelling rationale for evaluating rucaparib, a potent PARP1, PARP2 and PARP3 inhibitor, in patients with mCRPC associated with homologous recombination deficiency. Alan presents the molecular selection criteria, the design of the trial and the initial look at the first 85 patients in this study of he...

A Review on Practice Informing Prostate Cancer Study Results - Christopher Sweeney

Details
(Length of Conversation: 18 min) Christopher Sweeney and Alicia Morgans review practice informing data released at the ESMO 2018 meeting from the GETUG 12, ERA 223, and STAMPEDE studies. Biographies: Christopher Sweeney, MBBS, Professor of Medicine, Harvard Medical School, Medical Oncologist, Dana-Farber Cancer Institute Alicia Morgans, MD, MPH Related Content: 12-Year Follow-Up of GETUG-12, A Pha...

The Prostate Cancer Foundation: a Discussion with Andrea Miyahira

Details
(Length of Discussion: 7 min) Andrea Miyahira and Alicia Morgans discuss the Prostate Cancer Foundation, the largest non-profit organization in the world, focused solely on funding for prostate cancer research and committed to advancing treatments for very late stage patients. Biographies: Andrea K. Miyahira, Ph.D., Dr. Andrea Miyahira has a Ph.D. in cancer immunology and is Director of Research a...

The Process of Metastasis in Prostate Cancer - Kenneth Pienta

Details
(Length of Discussion: 16 min) Charles Ryan and Ken Pienta discuss the process of metastasis in prostate cancer, referring to the seed and soil hypothesis and the influence of the tumor microenvironment and immune system. Biography: Kenneth J. Pienta, MD, The Donald S. Coffey Professor of Urology, Professor of Oncology, Professor of Pharmacology and Molecular Sciences, The Johns Hopkins Hospital R...